JIS T 2304:2026 Takes Effect: Medical Device Websites Must Complete Trilingual Clinical Summaries

On July 22, 2026, the Japanese Ministry of Economy, Trade and Industry (METI) brought the JIS T 2304:2026 standard into effect, subjecting B2B independent websites selling Class II and higher medical devices to Japanese medical institutions to more clearly defined online information disclosure requirements. The changes focus not only on webpage presentation itself, but also extend to clinical evidence organization, compliance verification, procurement communication, and delivery preparation. For medical device companies exporting to Japan, channel platforms, certification and testing service providers, and procurement parties, this is more like a rule change that has already entered the implementation stage. They need to promptly assess whether their existing product pages, document packages, and review processes can be effectively aligned.

What specific webpage content is covered by the new requirements

According to the information provided, the Japanese Ministry of Economy, Trade and Industry (METI) brought the JIS T 2304:2026 standard into effect on July 22, 2026. The standard requires all B2B independent websites selling Class II and higher medical devices to Japanese medical institutions to provide summaries of clinical evidence in Japanese, English, and Chinese simultaneously on product pages.

The content confirmed as required for inclusion on the summary page includes the PMDA approval number, qualifications of the testing institution, and a sample size description. In addition, the summary page must be verified through a JIS-certified third-party verification pop-up window. These requirements concern the presentation and verification arrangements of B2B independent websites selling to Japanese medical institutions. The information provided does not include more detailed implementation rules, transition arrangements, or exceptions.

Which business processes are affected beyond the webpage requirements

For exporters and website operators, the initial impact falls on document organization and page compliance

From an industry perspective, for export companies conducting online customer acquisition or product presentation directly to Japanese medical institutions, the most direct change is that product pages are no longer merely marketing presentation pages but also carry a clearer obligation to provide summaries of clinical evidence. The impact will be reflected in multilingual content preparation, synchronized product-page updates, clinical document summarization, and the integration of verification pop-up windows. Companies currently need to focus not only on whether they possess the relevant materials, but also on whether the materials can be presented consistently in Japanese, English, and Chinese and disclosed in synchronization with the product pages.

For certification and testing service providers, the focus shifts to the verification chain and consistency of wording

The summary page is required to be verified through a JIS-certified third-party verification pop-up window. This means that certification, testing, or related compliance service companies may become more involved in the verification chain for online information presentation. The main impacts concern verification methods, document integration, page verification display, and compliance recordkeeping. For relevant service providers, it is necessary to monitor the correspondence between the summary content and the verification results and avoid disconnects between the product-page presentation, summary content, and verification status.

For procurement and channel processes, attention will extend from quotations to the verifiability of evidence

For Japanese medical institution procurement departments and companies responsible for distribution and channel communication, the rule change may increase attention to the completeness of evidence summaries during initial online screening. The impact will mainly appear in product selection comparisons, document retrieval, pre-procurement communication, and internal review preparation. Practical changes to monitor include whether the product page displays the trilingual summary simultaneously, whether the summary contains the specified elements, and whether basic verification can be completed through the third-party verification pop-up window.

For delivery and after-sales coordination, document consistency risks should be addressed in advance

Although the information provided does not specify clear provisions regarding delivery and after-sales service, once online product pages are included in standardized disclosure requirements, companies generally need to maintain consistency in external information throughout subsequent technical document submission, procurement document responses, after-sales explanations, and quality traceability. For processing and manufacturing companies, supply chain service providers, and after-sales service providers, the more important issues at present are document version management and unified external messaging, rather than simply treating the requirement as a website revision.

Which practical changes should companies focus on now

First verify which products and website pages fall within the scope of the requirements

Companies should first identify which products are Class II or higher medical devices sold to Japanese medical institutions and which business activities use B2B independent websites for presentation, inquiry acquisition, or procurement communication. From an analytical perspective, only after the scope of the products and pages has been identified can subsequent trilingual summary supplementation, compliance review, and verification integration have clear targets.

Convert clinical evidence summaries from attached documents into verifiable front-end information

The key point at present is that the requirement does not stop at back-office archiving. It requires summaries to be provided simultaneously on product pages and clearly list the PMDA approval number, qualifications of the testing institution, and sample size description. Companies need to check whether their existing technical documents, registration materials, or sales materials already contain standardized wording suitable for front-end display and whether the three language versions can maintain content consistency.

Pay attention to the page and process changes brought by the third-party verification pop-up window

The third-party verification pop-up window means that compliance actions need to be incorporated into the website front-end presentation and user access path. Companies should assess whether adjustments are needed to site development, page launch review, compliance recordkeeping, and subsequent update mechanisms. Since the information provided does not specify more detailed technical implementation requirements, it is currently more appropriate to understand this as the need to reserve the capability for verification integration and continuous updates, rather than assuming that a specific fixed implementation method has already been established.

Make version consistency across procurement, bidding, and delivery documents a priority

For companies involved in procurement responses, long-term supply, or multi-party coordinated delivery, it is advisable to check whether there are differences in wording among the product-page summary, technical documents, external quotation materials, and after-sales explanations. From an analytical perspective, such rule changes may first expose problems on front-end pages, but the real pressure often emerges during procurement review and delivery coordination. Companies therefore need to establish unified version management at an early stage.

This is more like an implementation signal than merely an information disclosure reminder

From an editorial perspective, this news is better understood as an implementation signal that has already taken effect, rather than simply a directional discussion. The reason is that the information provided specifies the effective date, applicable entities, summary elements, and third-party verification pop-up window requirements, indicating that the focus of the rules has moved from principle-based wording to webpage presentation and verification methods.

At the same time, it should be noted that the information provided does not include more detailed implementation requirements, such as the summary format, verification process details, update frequency, or actual review methods. Therefore, the industry should neither treat this as a long-term development that has not yet taken effect nor draw too many unconfirmed operational conclusions from it. Continued attention is still required regarding certification implementation practices, changes to procurement documents, and the actual implementation status of companies.

Practical implications for market participants

Overall, the implementation of JIS T 2304:2026 signals that online B2B presentation of medical devices in Japan is being incorporated into a more specific compliance framework. Its impact is not limited to a single webpage module, but concerns the coordination among product information disclosure, clinical evidence organization, third-party verification, procurement communication, and document consistency management.

Therefore, it is currently more appropriate to understand this news as a rule change that has entered the implementation stage, as well as a regulatory development whose subsequent detailed rules and market feedback still require continued observation. For relevant companies, the short-term priority is not to broaden the interpretation, but to first complete applicability assessment, document verification, and webpage compliance preparation.

Basis of this article and directions for further verification

This article was generated based on the information title, event date, and event summary provided by the user. The known information includes the effective date of JIS T 2304:2026, its applicable entities, the requirement for trilingual clinical evidence summaries, the specific elements that the summaries should contain, and the requirement for verification through a JIS-certified third-party verification pop-up window.

For events of this type, continued verification would normally also require reference to official announcements, publications issued by regulatory authorities, information from trade authorities, industry association information, documents issued by standards organizations, and reports from authoritative media. Since no specific official source links were provided in the input, this article cannot further confirm the full text of the original documents, supporting explanations, or links to implementation rules. Continued attention is still needed regarding policy details, certification implementation practices, changes to tender documents, industry feedback, and the actual implementation status of companies.